SALIVARY FLOW AND COMPOSITION IN LYMPHOMA PATIENTS BEFORE, DURING AND AFTER TREATMENT WITH CYTOSTATIC DRUGS

被引:19
作者
LAINE, P
MEURMAN, JH
TENOVUO, J
MURTOMAA, H
LINDQVIST, C
PYRHONEN, S
TEERENHOVI, L
机构
[1] UNIV TURKU,INST DENT,SF-20520 TURKU 52,FINLAND
[2] HELSINKI UNIV,CENT HOSP,DEPT ONCOL & RADIOTHERAPY,SF-00290 HELSINKI,FINLAND
[3] HELSINKI UNIV,CENT HOSP,DEPT ORAL & MAXILLOFACIAL SURG,SF-00130 HELSINKI,FINLAND
[4] UNIV KUOPIO,INST DENT,SF-70211 KUOPIO,FINLAND
[5] UNIV HELSINKI,INST DENT,SF-00300 HELSINKI,FINLAND
来源
ORAL ONCOLOGY-EUROPEAN JOURNAL OF CANCER PART B | 1992年 / 28B卷 / 02期
关键词
D O I
10.1016/0964-1955(92)90040-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To investigate the effect of modern, intensive chemotherapy on salivary flow rate and composition, 79 patients suffering from Hodgkin's disease or non-Hodgkin lymphoma were studied before, during and after administration of cytostatic drugs. 49 patients (mean age 49.9 years, 30 men, 19 women) completed the 1-year study. All patients who received radiotherapy or medication other than cytostatics were excluded. The results showed no marked differences in stimulated salivary flow rates, buffering capacities and amylase and total protein concentrations between the beginning and the end of the 12 month trial. However, significant increases in albumin secretion into saliva and salivary lysozyme concentrations were observed. Total salivary IgG, IgA and IgM concentrations decreased significantly during the cancer therapy but values returned to the baseline levels after termination of treatment. Despite the well-known cytolytic effect of anticancer drugs, chemotherapy need not therefore be permanently detrimental to saliva.
引用
收藏
页码:125 / 128
页数:4
相关论文
共 21 条
[1]  
BALIS FM, 1988, PEDIATR CLIN N AM, V35, P835
[2]  
Baum B J, 1985, Spec Care Dentist, V5, P274, DOI 10.1111/j.1754-4505.1985.tb00593.x
[4]   XEROSTOMIA - EVALUATION OF A SYMPTOM WITH INCREASING SIGNIFICANCE [J].
FOX, PC ;
VANDERVEN, PF ;
SONIES, BC ;
WEIFFENBACH, JM ;
BAUM, BJ .
JOURNAL OF THE AMERICAN DENTAL ASSOCIATION, 1985, 110 (04) :519-525
[5]  
IZUTSU KT, 1981, CANCER, V48, P1450, DOI 10.1002/1097-0142(19810915)48:6<1450::AID-CNCR2820480629>3.0.CO
[6]  
2-M
[7]   THE PHARMACOLOGY AND CLINICAL USE OF METHOTREXATE [J].
JOLIVET, J ;
COWAN, KH ;
CURT, GA ;
CLENDENINN, NJ ;
CHABNER, BA .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (18) :1094-1104
[8]   AMOUNT AND AVIDITY OF SALIVARY AND SERUM ANTIBODIES AGAINST STREPTOCOCCUS-MUTANS IN 2 GROUPS OF HUMAN-SUBJECTS WITH DIFFERENT DENTAL-CARIES SUSCEPTIBILITY [J].
LEHTONEN, OP ;
GRAHN, EM ;
STAHLBERG, TH ;
LAITINEN, LA .
INFECTION AND IMMUNITY, 1984, 43 (01) :308-313
[9]  
LOWRY OH, 1951, J BIOL CHEM, V193, P265
[10]  
MAKKONEN TA, 1986, ORAL SURG ORAL MED O, V62, P270, DOI 10.1016/0030-4220(86)90007-1